| Entry |
|
|---|
| Name |
Urapidil hydrochloride;
Ebrantil (TN) |
|---|
| Formula |
C20H29N5O3. HCl
|
|---|
| Exact mass |
423.2037
|
|---|
| Mol weight |
423.94
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG01739 Peripherally-acting antiadrenergic
DG03231 Antihypertensive
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
|
|---|
| Remark |
| Product (DG00257): | D01333<JP> |
|
|---|
| Efficacy |
Antihypertensive, alpha1-Adrenergic receptor antagonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07215 | alpha-Adrenergic receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C02 ANTIHYPERTENSIVES
C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02CA Alpha-adrenoreceptor antagonists
C02CA06 Urapidil
D08662 Urapidil hydrochloride
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00257 Urapidil
D08662 Urapidil hydrochloride
DG01739 Peripherally-acting antiadrenergic
DG00257 Urapidil
D08662 Urapidil hydrochloride
DG03231 Antihypertensive
DG00257 Urapidil
D08662 Urapidil hydrochloride
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00257 Urapidil
D08662 Urapidil hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D08662 Urapidil hydrochloride
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08662
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00257 Urapidil
DG01739 Peripherally-acting antiadrenergic
DG00257 Urapidil
DG03231 Antihypertensive
DG00257 Urapidil
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00257 Urapidil
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 29
1 C8x C 16.2400 -21.4200
2 C8x C 16.2400 -20.0200
3 C8y C 17.5000 -19.3200
4 C8y C 18.6900 -20.0200
5 C8x C 18.6900 -21.4200
6 C8x C 17.5000 -22.1200
7 N1y N 19.8800 -19.3200
8 C1x C 19.8800 -17.9200
9 C1x C 21.1400 -17.2200
10 N1y N 22.3300 -17.9200
11 C1x C 22.3300 -19.3200
12 C1x C 21.1400 -20.0200
13 C1b C 23.5200 -17.2200
14 C1b C 24.7800 -17.9200
15 C1b C 25.9700 -17.2200
16 N1b N 27.1600 -17.9200
17 C8y C 28.4200 -17.2200
18 C8x C 28.4200 -15.8200
19 C8y C 29.6100 -15.1200
20 N4y N 30.8000 -15.8200
21 C8y C 30.8000 -17.2200
22 N4y N 29.6100 -17.9200
23 C1a C 29.6100 -19.3200
24 O5x O 32.0600 -17.9200
25 C1a C 32.0600 -15.1200
26 O5x O 29.6100 -13.7200
27 O2a O 17.5000 -17.9200
28 C1a C 16.3100 -17.2200
29 X Cl 34.3000 -20.5100
BOND 30
1 13 14 1
2 4 7 1
3 14 15 1
4 1 2 2
5 15 16 1
6 2 3 1
7 16 17 1
8 3 4 2
9 4 5 1
10 5 6 2
11 7 8 1
12 8 9 1
13 17 18 2
14 18 19 1
15 19 20 1
16 20 21 1
17 21 22 1
18 22 17 1
19 9 10 1
20 22 23 1
21 10 11 1
22 21 24 2
23 11 12 1
24 20 25 1
25 12 7 1
26 19 26 2
27 6 1 1
28 3 27 1
29 10 13 1
30 27 28 1
|
|---|